12 Dirt Cheap Stocks to Buy Now

Page 5 of 11

7. Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) is one of the dirt cheap stocks to buy now. On February 11, Royalty Pharma reported a year of robust financial performance in 2025, marked by a 16% increase in total portfolio receipts and an 18% jump in Q4 alone. The company achieved a notable 15.8% return on invested capital and successfully met its five-year $10 billion to $12 billion capital deployment target a full year ahead of schedule.

Strategically, the company completed $4.7 billion in transactions focused on attractive therapies and received a boost from several positive clinical and regulatory milestones, including the FDA approval of Myqorzo. Management highlighted the growing importance of synthetic royalties, which the company views as an increasingly popular alternative to traditional debt or equity financing for biotech firms.

Despite this momentum, the company is preparing for some headwinds in 2026, including the loss of exclusivity for Promacta and the introduction of a biosimilar for Tysabri in the US market. In 2026, Royalty Pharma expects portfolio receipts to range between $3.275 and $3.425 billion, representing a modest growth forecast of 3% to 8%.

Royalty Pharma (NASDAQ:RPRX) operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the US.

Page 5 of 11